Amgen Inc. (AMGN)
|Net Income (ttm)||5.61B|
|Ex-Dividend Date||Nov 15, 2021|
|Day's Range||200.52 - 206.00|
|52-Week Range||200.47 - 276.69|
|Price Target||244.81 (+21.7%)|
|Earnings Date||Nov 2, 2021|
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment o... [Read more...]
In 2020, Amgen's revenue was $25.42 billion, an increase of 8.83% compared to the previous year's $23.36 billion. Earnings were $7.26 billion, a decrease of -7.37%.Financial Statements
According to 30 analysts, the average rating for Amgen stock is "Buy." The 12-month stock price forecast is 244.81, which is an increase of 21.74% from the latest price.
Amgen beat analysts' earnings expectations in the third quarter, and its balance sheet remains admirable.
THOUSAND OAKS, Calif., Nov. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Evercore ISI Healthcare Conference at 5:10 p.m.
THOUSAND OAKS, Calif., Nov. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Piper Sandler Healthcare Conference at 1:00 p.m.
THOUSAND OAKS, Calif., Nov. 17, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the awarding of a one-time $25,000 grant to the Bath Institute of Rheumatic Diseases (BIRD) as part of the Unders...
The CHMP gives a positive opinion on, and recommends approval to Amgen's (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.
These health care industry players continue to serve the masses amid the current pandemic.
LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small ...
THOUSAND OAKS, Calif., Nov. 12, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a posit...
Two of them have already been big winners for investors this year.
The big biotech reported only modest sales growth.
THOUSAND OAKS, Calif., Nov. 10, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 annual Cowen IO Summit at 2:15 p.m.
First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway ...
THOUSAND OAKS, Calif., Nov. 8, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the HER-MES study, the first and only head-to-head study of Aimovig® (erenumab-aooe), a calcitonin g...
Biotech stocks have been picking up steam lately and several positive catalysts could keep the wind at the industry's back. Here are five names analysts are bullish on right now.
THOUSAND OAKS, Calif., Nov. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio.
A proposed cap on out-of-pocket drug costs for Medicare recipients would improve patient access, but allowing the U.S. government health plan for seniors to negotiate prices could limit innovation, Amge...
Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.
Amgen Inc's (NASDAQ: AMGN) Q3 revenues increased 4% to $6.71 billion, slightly beating the consensus of $6.68 billion. The increase is driven by higher unit demand, partially offset by lower net selling...
Amgen (AMGN) delivered earnings and revenue surprises of 10.66% and 0.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Amgen (NASDAQ:AMGN) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Amgen Inc on Tuesday reported a 4% increase in third-quarter revenue as the impact of the COVID-19 pandemic on drug prescriptions began to ease, but said prices for some of its drugs remained under pres...
THOUSAND OAKS, Calif., Nov. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2021.